Dr. Pansegrau has disclosed that his spouse receives research funding from AstraZeneca. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Davies C, Pan H, Godwin J et al.. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805–816.
Gray RG, Rea D, Handley K et al.. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 in 6,953 women with early breast cancer [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 5.
Goss PE, Ingle JN, Martino S et al.. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 2013;24:355–361.
Kwon JS, Pansegrau G, Nourmoussavi M et al.. Long-term consequences of ovarian ablation for premenopausal breast cancer. Breast Cancer Res Treat 2016;157:565–573.
Haldar K, Giamougiannis P, Wilson C, Crawford R. Laparoscopic salpingo-oophorectomy for ovarian ablation in women with hormone-sensitive breast cancer. Int J Gynaecol Obstet 2011;113:222–224.
Healthcare Bluebook. Fair Price search tool. Available at: https://healthcarebluebook.com/page_ConsumerFront.aspx. Accessed February 28, 2017.
King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005;25:667–677.
Weinstein MC, Siegel JE, Gold MR et al.. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253–1258.
Goss PE, Ingle JN, Martino S et al.. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–1271.
Colleoni M, Sun Z, Price KN et al.. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol 2016;34:927–935.
Pan H, Gray RG, Davies C et al.. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET) [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 505.
Social Security Administration. Actuarial Life Table. Available at: http://www.socialsecurity.gov/OACT/STATS/table4c6.html. Accessed March 9, 2017.
Parker WH, Feskanich D, Broder MS et al.. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses' Health Study. Obstet Gynecol 2013;121:709–716.
SEER. Cancer Stat Facts: Female Breast Cancer. Available at: http://seer.cancer.gov/statfacts/html/breast.html. Accessed June 23, 2016.
Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 2011;103:1397–1402.
Chlebowski RT, Pan K, Col NF. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. Breast Cancer Res Treat 2017;161:185–190.
Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996;348:1189–1196.
Pagani O, Regan MM, Walley BA et al.. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;37:107–118.
Writing Group Members Mozaffarian D, Benjamin EJ et al.. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 2016;133:447–454.
GoodRx. Available at: http://www.goodrx.com/. Accessed February 28, 2017.